

University of Groningen

The assessment of oral squamous cell carcinoma

Boeve, Koos

DOI:
[10.33612/diss.135865241](https://doi.org/10.33612/diss.135865241)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Boeve, K. (2020). *The assessment of oral squamous cell carcinoma: A study on sentinel lymph node biopsy, lymphatic drainage patterns and prognostic markers in tumor and saliva*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.135865241>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

CHAPTER 3

High sensitivity and negative predictive value of sentinel lymph node biopsy in a retrospective early stage oral cavity cancer cohort in the Northern Netherlands

SLNB in early stage oral cavity cancer

K. Boeve^{1,2}, K.P. Schepman¹, E. Schuurin², J.L.N. Roodenburg¹, G.B. Halmos³, B.A.C. van Dijk^{4,5}, R.A.C. Boorsma⁶, J.G.A.M. de Visscher⁷, A.H. Brouwers⁸, B. van der Vegt², M.J.H. Witjes¹

Adapted version as published in *Clinical Otolaryngology*.2018;43:1080–1087. DOI: 10.1111/coa.13107. Epub 2019 Mar 25.

Departments of Oral and Maxillofacial Surgery¹, Pathology & Medical Biology², Otorhinolaryngology / Head & Neck Surgery³, Epidemiology⁴ and Nuclear Medicine & Molecular Imaging⁵, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Department of Research⁵, Comprehensive Cancer Organization The Netherlands (IKNL), Utrecht, The Netherlands. Pathologie Friesland⁶, Leeuwarden, The Netherlands. Department of Oral and Maxillofacial Surgery⁷, Medical Center Leeuwarden, Leeuwarden, The Netherlands.

ABSTRACT

Objectives: In cT1-2N0 oral squamous cell carcinoma (OSCC) occult metastases are detected in 23-37% of cases. Sentinel lymph node biopsy (SLNB) was introduced in head and neck cancer as a minimally invasive alternative for an elective neck dissection in neck staging. Meta-analyses of SLNB accuracy show heterogeneity in the existing studies for reference standards, imaging techniques and pathological examination. The aim of this study was to assess the sensitivity and negative predictive value (NPV) of the SLNB in detecting occult metastases in cT1-2N0 OSCC in a well-defined cohort.

Design: Retrospective study. The SLNB procedure consisted of lymphoscintigraphy, SPECT-CT scanning and gamma probe detection. Routine follow-up was the reference standard for the SLNB negative neck. Histopathological examination of sentinel lymph nodes (SLN) consisted of step serial sectioning, haematoxylin-eosin and cytokeratin AE1/3 staining.

Setting: Two comprehensive oncology centres.

Participants: A total of 91 consecutive patients with primary cT1-2N0 OSCC treated by primary resection and neck staging by SLNB procedure between 2008 and 2016.

Main outcome measures: Sensitivity and negative predictive value.

Results: In all cases, SLNs were harvested. A total of 25 (27%) patients had tumour-positive SLNs. The median follow-up was 32 months (range 2-104). Four patients were diagnosed with an isolated regional recurrence in the SLNB negative neck side resulting in an 85% sensitivity and a 94% NPV.

Conclusion: In our cohort, the SLNB detected occult metastases in early OSCC with 85% sensitivity and 94% NPV. This supports that SLNB is a reliable procedure for surgical staging of the neck in case of oral cT1-2N0 SCC.

INTRODUCTION

Regional metastases occur in 23-37% of the early stage (cT1-2N0) oral squamous cell carcinomas (OSCC) [1-3]. Lymph node status is an important prognostic factor for outcome and treatment decision making of head and neck cancer [1-8]. However, not all metastases are clinically detectable with the current diagnostic modalities [9-11]. Occult metastases are conventionally treated by removal of the lymph nodes by elective neck dissection (END) after research showed higher rates of overall and disease specific survival compared to a watchful waiting strategy [12]. However, an END has disadvantages: it leads to overtreatment in 63-77% of the cases and has a risk of postoperative morbidity (e.g. shoulder pain, reduced limb movement) [13]. Therefore, there is a need for a better neck staging modality.

The sentinel lymph node biopsy (SLNB) was introduced in oral cavity cancer as a less invasive lymph node staging technique after successful implementation in melanoma and breast cancer [5]. The limited number of lymph nodes (LN) with the SLNB enables a more meticulous pathological examination incorporating step serial sectioning (SSS) and additional immunohistochemistry (IHC) [14]. Recently, Liu and Wang reported a meta-analysis of 3566 early stage OSCC patients from 66 studies with a pooled sensitivity of 87% and negative predictive value (NPV) of 94% for SLNB in detecting occult metastasis [15]. However, many of these studies consist of small cohorts and differ in reference treatment, SLNB localisation technique (e.g. use of gamma-probe, blue dye or single photon emission CT (SPECT-CT)) and pathological work-up (with or without IHC or SSS). Furthermore, several studies provide incomplete clinico-pathological information. This heterogeneity and lack of complete data underline the need for more studies using complete and homogeneous cohorts. The aim of this study was to determine the sensitivity and NPV of the SLNB in detecting occult metastases in a large, well-defined cohort. For this purpose, we used a retrospective cT1-2N0 OSCC cohort of 91 patients all treated by primary surgical resection, neck staging with the SLNB procedure and routine follow-up as reference standard for the SLNB negative neck.

PATIENTS AND METHODS

Ethical consideration

Sentinel lymph node biopsy was part of standard treatment and data were retrospectively gathered from existing data sources; therefore no approval from the hospital research ethics board was required according to the Dutch ethical regulations [16,17]. Five patients were

also included in a Dutch multicenter SNLB validation trial before the SLNB was incorporated in the Dutch guidelines. Written informed consent was obtained from each of these five individual patients after study approval from the ethical board of the UMCG [7].

Patients and setting

Patients treated at the Oral & Maxillofacial Surgery or Otorhinolaryngology / Head & Neck Surgery departments of the University Medical Center Groningen (UMCG) (n = 91) or the Oral & Maxillofacial Surgery department of the Medical Center Leeuwarden (MCL) (n = 12) between October 2008 and September 2016 were included. Inclusion criteria: clinically T1-2N0 OSCC; primary treatment by surgical resection; neck staging by SLNB. Twelve patients were excluded because of pT3-4 tumours (n = 2), multiple primary head and neck squamous cell carcinoma at diagnosis (n = 5), incomplete SLNB protocol (n = 3) and, multifocal tumours without free surgical resection margins and uncertainty of clear injection around the tumour (n = 2). Clinico-pathological data of the 91 (100%) patients were retrospectively collected from the digital patients files (Table 1). Clinical neck staging was performed by extensive palpation and CT or MRI (UMCG) or by ¹⁸F-FDG positron emission tomography (PET)-CT (MCL) scanning and in both centers followed by US-guided with fine needle aspiration cytology in case of enlarged (>1 cm) of otherwise suspicious nodes. Cases with a positive SNLB underwent a modified radical neck dissection (MRND) during a second surgery. Routine follow-up of the neck was used as reference standard in the SLNB negative patients. In total seven (8%) patients received adjuvant radiotherapy for irradiated tumour resection of the deep margin (n = 4), pN2 neck stage (n = 3) and/or extranodal extension (n = 1).

Sentinel lymph node biopsy procedure

One day before surgery ^{99m}Tc-nannocolloid (median 100 MBq, IQR 95-102, data available for 90 patients) (GE Healthcare, The Netherlands) was injected around the tumour. Dynamic visualization by lymphoscintigraphy followed immediately after injection for 20 minutes in anterior or oblique views (20x60s, 128x128 matrix) and also immediately static images (300 s, 256x256m matrix) in anterior and lateral direction were generated (Ecam or Symbia S (MCL), or SymbiaT (UMCG), Siemens, Knoxville, TN, USA). The static visualization was repeated after 2-4 h. Thereafter visualization by SPECT-CT scanning of the head and neck using a two-headed gamma camera equipped with parallel-hole ultra-high resolution collimators and a 2-slice CT scanner (32 views of 20 s, 128x128 matrix; mAs 30, kV 110, 3.0 mm slice) was performed, only in the UMCG. SPECT-CT scanning was added to the protocol after treatment of the first five patients. The position of the SLN was marked on the overlaying skin with a Cobalt-57 point-source-marker and a gamma-probe (Europrobe, EuroMedical Instruments, France (MCL) and Neoprobe, Mammotome, Cincinnati, Ohio (UMCG)). The first lymph nodes in a lymphatic path from the tumour were marked as SLNs.

Table 1. Patient and tumour demographic characteristics

Demographic Characteristics	Overall, n (%)	Histopathological status of SLNB		
		pN0, n (%)	pN+ (%)	p-value
Total	91 (100)	66 (100)	25 (100)	NA
Sex				
Male	43 (48)	32 (48)	11 (44)	0.815
Female	48 (52)	34 (52)	14 (56)	
Age at first treatment, y				
median (IQR)	62 (56-70)	61 (56-71)	64 (57-69)	0.996
Tumour location n(%)				
Tongue	52 (57)	35 (53)	17 (68)	0.111*
FOM	27 (30)	23 (35)	4 (16)	
Cheek mucosa	8 (9)	5 (8)	3 (12)	
Upper gum	3 (3)	2 (3)	1 (4)	
Lower gum	1 (1)	1 (2)	0 (0)	
cT classification				
cT1	66 (73)	51 (77)	15 (60)	0.119
cT2	25 (27)	15 (23)	10 (40)	
pT classification				
pT1	73 (80)	57 (86)	16 (64)	0.036
pT2	18 (20)	9 (14)	9 (36)	
SLNB side				
Ipsilateral	57 (63)	40 (61)	17 (68)	0.701
Contralateral	1 (1)	1 (2)	0 (0)	
Both sides	33 (36)	25 (38)	8 (32)	
Number of SLNs per patient				
Median (IQR)	3 (2-4)	3 (2-4)	3 (2-4)	0.585
Tumour infiltration depth				
<4.59 mm	59 (65)	46 (70)	13 (52)	0.142
≥4.59 mm	32 (35)	20 (30)	12 (48)	
Perineural invasion				
Yes	6 (7)	3 (5)	3 (12)	0.340
No	85 (93)	63 (95)	22 (88)	
Lymphovascular invasion				
Yes	9 (10)	6 (9)	3 (12)	0.702
No	82 (90)	60 (91)	22 (88)	

Table 1. Continued

Demographic Characteristics	Overall, n (%)	Histopathological status of SLNB		
		pN0, n (%)	pN+ (%)	p-value
Tumour border configuration				
Pushing	54 (59)	45 (68)	9 (36)	0.008
Infiltrative	37 (41)	21 (32)	16 (64)	
Differentiation grade				
Well	29 (32)	21 (32)	8 (32)	1.000
Moderate	62 (68)	45 (68)	17 (68)	
Follow up data				
Time in months <i>median (IQR)</i>	32 (21-47)	37 (22-49)	25 (19-33)	0.014
total range	2-104			
Recurrence				
Local / 2nd primary	9 (10)	5 (8)	4 (16)	**
Isolated regional rec.	5 (5)	2 (3)	3 (12)	
Dead				
Dead of disease	3 (3)	0 (0)	3 (12)	**
Dead not of disease	7 (8)	6 (9)	1 (4)	

Abbreviations: SLNB: sentinel lymph node biopsy. pN0: SLNs negative for metastases. pN+: SLNs positive for metastases. NA: not applicable. IQR: interquartile range. FOM: floor of mouth. Rec: recurrence

*: Tongue vs floor of mouth, other subgroups too small to analyse. **: Group too small to analyse

Surgical procedure

SLNs were harvested with a small incision in the neck after gamma probe assisted localization. The neck side of the SLNB was indicated by the results of the lymphoscintigraphy. In 28 (31%) patients, non-SLNs were harvested due to location of the SLN in a conglomerate of lymph nodes or the impossibility to remove the SLNs without harvesting these non-SLNs. SLNs were separated from the non-SLNs *ex vivo* using the gamma-probe in the operation theatre. Finally, the neck background radioactivity was checked with the gamma-probe to make sure that no SLN was left behind. Blue-dye was used intra-operatively in fourteen patients but not on regular base in both hospitals.

Histopathological procedure

SLNs were histopathologically examined by step serial sectioning of the entire SLNs with an interval of 500 μ m, conventional staining with hematoxyline-eosine (H&E) and an additional pan-cytokeratin antibody (AE 1/3) immunohistochemistry staining. The non-SLNs were

examined according to the SLN protocol in four patients and using standard H&E without IHC or step serial sectioning in 24 patients. MRND lymph nodes were examined using the routine protocol. Histology of all SLNs and primary tumours was revised by a head and neck pathologist (BvdV). Lymph node metastases were classified according to Hermanek; ITC's <0.2 mm, micrometastasis 0.2-2 mm and macrometastasis >2 mm [18]. Infiltrative tumour border configuration was defined according to the classification of Heerema: small groups or cords of infiltration cells, widespread cellular dissociation in small groups of cells or in single cells and tumor satellites or any size ≥ 1 mm away from main tumour [19]. 4.59 mm was used as tumour infiltration depth cut-off according to Melchers [20].

Statistical analysis

IBM SPSS Statistics 23 (Statistical Package for the Social Sciences, Inc., Chicago, IL, USA) was used for analysis. Categorical data are presented as number (n) and their percentages (%). Associations between categorical data were tested with the Fisher's exact or Chi-squared test. Continuous data were tested using the Student's *t* test or the Mann-Whitney U test for normally or skewed distributed data, respectively. False negative SLNB patients were defined as patients with isolated regional recurrence in the SLNB negative neck side and were used to calculate the sensitivity and negative predictive value. Significant differences were defined as a *p*-value ≤ 0.05 .

RESULTS

Sentinel lymph nodes were identified in all 91 cases (100%). In total 274 SLNs were harvested with a median of 3 (range 1-11) per patient. The results of the SLN procedures are summarised in Table 1. In all patients, at least one SLN was intraoperatively detected. However, in 4 patients (4%) additional hotspots were noticed besides the harvested SLNs on the SPECT-CT without intraoperative detectable radioactive LNs. In 1 of these 4 patients, the harvested SLN was positive and the neck was treated by MRND in a second operation. The other 3 patients were isolated regional recurrence (IRR) free after 10, 11 and 47 months of routine follow-up. In one patient with a ventral floor of mouth tumour, only a contralateral SLN was identified. The other patients had ipsilateral (*n* = 57, 63%) or bilateral (*n* = 33, 36%) located SLNs.

Positive SLNs were found in 25 (27%) patients. In 1 patient with a 1 mm metastasis in the SLN routine follow-up was chosen instead of a MRND. This patient was still recurrence free after 23 months. In none of the patients with micrometastases or ITCs in the SLN additional metastases were found in the MRND specimen (Figure 1, Table 2, *p* = 0.024). Also, none of the 57 non-SLNs harvested during the SLNB were positive. Finally, skip metastases were

not seen: all patients with positive SLNs had at least one positive SLN in level I-III. Infiltrative tumour border configuration ($p = 0.008$) and pT2 tumour stage ($p = 0.036$) showed an association with lymph node status (Table 1).




Figure 1. Flowchart of the UMCG and MCL cT1-2N0 oral squamous cell carcinoma cohort.

In total 91 patients were used for analysis. A total of 25 patients had metastasis positive SLNB. Two patients with pN0 and two patients with pN+ SLNB neck status were diagnosed with isolated regional recurrence in the SLNB negative neck side.

Abbreviations: pN0: All SLNs negative for metastasis. pN+: at least one SLN positive for metastasis. MRND: modified radical neck dissection. SLNB: sentinel lymph node biopsy

Table 2. Association between SLN metastasis size and additional metastases in modified radical neck dissection lymph nodes

SLN status	n (%)	MRND lymph node status		p-value
		pN0, n (%)	pN+, n (%)	
Isolated Tumour Cells	7 (29)	7 (37)	0 (0)	0.024
Micrometastases	6 (25)	6 (32)	0 (0)	
Macrometastases	11 (46)	6 (32)	5 (100)	

Abbreviations: SLN: sentinel lymph node. MRND: modified radical neck dissection. pN0: LNs negative for metastases. pN+: LNs positive for metastases.

Follow-up and regional recurrence

Overall the median FU was 32 months (IQR 21-47, Range 2-104, Table 1). All patients with a follow-up <10 months died. In total, 8 (9%) patients of this cohort died. Three patients died of disease, two 10 months and one 21 months after the initial treatment.

Local recurrence and second primary tumours, with or without regional recurrence, were seen in 9 (10%) cases. Isolated regional recurrence was detected in 5 (5%) patients. One of these patients had IRR after a positive SLN and subsequent neck dissection at that neck side. The other 4 patients were diagnosed with IRR after 4, 6, 9 and 19 months. Their tumour, treatment and recurrence characteristics are shown in Table 3. The first patient had a positive ipsilateral SLN and was 4 months later diagnosed with level I and level II IRRs at the contralateral side. Revision of the SPECT-CT images and the conventional CT images of the IRR did not reveal new insights. The second patient had ipsilateral negative SLNs and was diagnosed with level Ib and level IV IRRs after 9 months. Revision of the SPECT-CT images of this patient showed a lymph node with a diameter of 7 mm without radioactivity just at the inside of the mandibular angle in level Ib. This lymph node was most likely not resected during the SLNB procedure and could be the same as the IRR lymph node. The third patient had a positive contralateral SLN. IRR occurred on the ipsilateral side, which was SLNB negative and was therefore not treated by MRND. Revision of the lymphoscintigraphy images revealed a low signal in level Ib at the ipsilateral side, what might be a missed SLN. The fourth patient had a negative SLN in level II and was diagnosed with IRR in level Ib, both ipsilateral. Revision of the SPECT-CT scan showed a LN within the radioactive hotspot of the floor of mouth tumour of this patient. Most likely, this is the same LN in which the IRR was diagnosed (Figure 2).

Due to the four IRRs, the SLNB detected occult metastases with 85% sensitivity and 94% NPV.

Table 3. Characteristics of the four patients with isolated regional recurrence

Variables	Patients with isolated regional recurrence			
	1	2	3	4
Tumour	Tongue	Cheek mucosa	Tongue	FOM
pT classification	1	1	2	2
Infiltration depth (mm)	8	5.0	3.7	2.7
Border growth	Pushing	Infiltrative	Infiltrative	Infiltrative
Resection margins	Free	Free	Free	Free
Perineural growth or Lympho- / angioinvasion	Yes, both	No	No	No
Differentiation grade	Good	Moderate	Moderate	Moderate
Reresection	Yes	No	No	No
Postoperative radiotherapy	Tumour & Neck	No	No	No
SLNB side	Ipsilateral	Ipsilateral	Both	Both
Positive SLN side	Ipsilateral	NA	Contralateral	NA
MRND side	Ipsilateral	NA	Contralateral	NA
Regional recurrence side	Contralateral	Ipsilateral	Ipsilateral	Ipsilateral
Number of SLNs recurrence side	NA	3	1	1
Number of positive SLNs recurrence side	NA	0	0	0
SLN level recurrence side	NA	Level II	Level II	Level II
Recurrence level	Level I + II	Level Ib + IV	Level Ib, II, IV	Level Ib
Number of LNs (positive / total)	2/44 (ENE+)	6/41	4/46	NA †
Maximum diameter regional recurrence metastasis (mm)	25	12	15	13 †
Time between 1st treatment and rec. (months)	4	9.2	5.5	19
Total follow-up (months)	27	36	9	25
Dead of disease	NA	NA	Yes	NA

Abbreviations: SLNB: sentinel lymph node biopsy. MRND: modified radical neck dissection. NA: not applicable. ENE: extranodal extension.

† The isolated regional recurrence of patient 4 was not operatively removed, therefore only clinical data was available.




Figure 2. Shine-through phenomenon example. Patient with a floor of mouth tumour on the left side close the midline (A), with a lymph node within the tumour hotspot (B) and an isolated regional recurrence after 19 months (C).

DISCUSSION

Synopsis of key findings

In our retrospective cohort of 91 patients treated for cT1-2N0 OSCC, 4 patients developed isolated regional recurrence on the side of a negative SLNB. This resulted in 85% sensitivity and 94% negative predictive value.

Comparison to previous studies

The sensitivity and NPV are in agreement with the results of other studies with routine follow up as a reference: sensitivity range 80-94% and NPV range 88-97.5% (number of patients 59-415) [1,6-8,21]. A recent meta-analysis also showed comparable results: sensitivity 87%, NPV 94% [15]. The slightly higher NPV of this cohort compared to these meta-analyses can be explained by the relative short follow-up of some patients in our cohort. Two of the 66 patients (3%) with routine follow up after a negative SLNB were diagnosed with IRR. This percentage is much lower than the conventional 20% change of having IRR from Weis et al, which is generally used in literature as threshold to choose between watchful waiting and END [22]. The low percentage IRR indicates the accurate selection of cT1-2N0 patients for neck dissection or routine follow up by performing a SLNB.

False negativity was defined as patients with IRR in an earlier SLNB negative neck side, regardless of a positive SLNB on the other side of the neck. Four (4%) patients in our cohort were diagnosed with IRR in a SLNB negative side of the neck, which is comparable with other studies [6,8]. Retrospectively, the reason for missing these regional metastases remains unclear; shine-through phenomenon and aberrant lymphatic drainage due to metastatic tumour in the SLNs might be involved. Another possible explanation might be micrometastases in lymph nodes, other than the SLN (skip metastases).

Other studies reported a lower sensitivity of the SLNB procedure in FOM tumours compared to other oral cavity subsites due to the shine-through phenomenon [7,8,23,24]. One patient in this study had a FOM with an IRR resulting in an 80% sensitivity and a 96% NPV for FOM tumours. Retrospectively, this SLNB was overlooked because of this shine-through phenomenon (Figure 2). To overcome shine-through and subsequent regional recurrences, Stoeckli et al. proposed a surgical technique with dissection of all the LNs in level I irrespective of the location of the SLNs [25]. Van den Berg et al., combined the SLNB procedure with radio- and fluorescence guidance and found this combination especially helpful in detecting SLNs located close to the primary tumour [26]. Our data support the findings of the previously mentioned studies [25,26], that patients with primary tumours adjacent to level I could benefit from additional techniques besides the SLNB procedure alone.

The upstaging rate in this study (27%) is in agreement with the literature; 23-37% [1,2,7,8]. We found no additional metastasis in the MRND lymph nodes after a SLNB positive for ITCs or micrometastases. Recently, den Toom et al. reported that the ratio of positive versus negative SLNs and the size of the tumour in the SLN possibly could be predictive factors for non-SLN metastasis in SLN positive patients. However, their analysis was underpowered due to the use of the ITC, micro- and macrometastasis classification in just a few SLNB studies [27]. No additional metastasis in ITC or micrometastasis SLN positive patients, could be the reason why Liu and Wang et al. concluded in their meta-analysis that SSS is not necessary for SLN assessment [15]. Despite the lack of impact of the SSS on the IRR rate, in agreement with den Toom and our data presented in this paper, SLN metastasis size might be used to select patients for routine follow-up instead of MRND [8]. Besides the SSS itself, also the step interval size could be discussed. After the second international conference on SLNB, intervals of 150 μm were recommended [28]. As was reported earlier for breast cancer, Jefferson et al. suggested that SSS intervals of 2 mm are thin enough to detect micrometastasis [29,30]. In this study intervals of 500 μm were used, because our head and neck SCC protocol was adapted from our vulvar SCC SLNB protocol. This is a protocol we have much experience with and has shown to provide accurate staging of vulvar SCC in our centre [31-33]. Besides this, the accuracy we found is comparable to that of most head and

neck SLNB studies [15]. Moreover, the ITC, micro- and macrometastasis ratio is comparable with other studies, indicating that we did not miss ITCs using this protocol. We therefore assume that this protocol has not influenced our results. However, we propose to continue SSS and classification of SLN metastasis size according to Hermanek, until well powered studies have defined the clinical impact of the SLN metastasis size [18]. Afterwards, further research is needed to reach consensus about minimal interval thickness for SSS to detect these metastases with clinical impact.

Thirty-three patients had SLNs on both sides of the neck, also in cases with lateralised border of tongue tumours. Moreover, 1 patient did not show ipsilateral lymphatic drainage patterns, but instead showed a negative contralateral SLN. This patient did not develop IRR at either side within 34 months follow-up. These 34 (37%) patients showed the advantage of detecting unexpected drainage patterns with the SLNB procedure and were thereby prevented from undertreatment.

Despite the good accuracy of the SLNB procedure, improvements might be made for the clinical negative neck. For example, in our centres the use of blue dye has been abandoned, because it blurred surgical tumour resection margins intra-operatively. A disadvantage of the SLNB procedure is the second operation for the MRND after a positive SLNB. Especially in frail elderly or patients with multiple comorbidities, a second operation with general anaesthesia is undesirable due to a higher complication and mortality chance [34]. Moreover in all positive cases, scar tissue makes the neck dissection surgery more challenging in the SLN levels. To avoid repeat surgery, the possibility of intraoperatively staging of SLNs with frozen sections has been studied [35]. However, frozen sections have a substantial false negative rate; therefore frozen sections of the SLNs are not applied in our centres. Also a substantial amount of the SLN is lost for the FFPE sections and thereby increasing the risk of missing ITCs and micrometastases [35].

In an ideal situation, patients at high risk of lymph node metastases are preoperatively selected for MRND or watchful waiting. In the current study, an infiltrative tumour border configuration or a pT2 tumour was significantly associated with more regional metastases. Our research group reported earlier infiltration depth and lymphovascular invasion as independent predictors for nodal status in pT1-2N0 and N-status determination by routine HKD and watchful waiting [20]. These markers are not associated with positive lymph nodes in this study. The lack of significance could be explained by the difference in patient selection between the mentioned study by Melchers (cN0 and cN+) and this study (cN0) [20]. Therefore, the SLNB procedure is still more accurate in detecting occult metastasis in

cT1-2N0 OSCC than the current clinical and pathological markers. In addition, it would be interesting to study the prognostic value of OSCC lymph node status associated biological markers such as *WISP1*, *RAB25* or *EpCAM* in cT1-2N0 OSCC SLNB staged patients [36-38].

Study limitations

Limitation of this study is that the SLNB procedure was not part of the standard workflow for cT1-2N0 OSCC patients in the first years after introduction. If we analyse the accuracy without the 6 patients from this period, the sensitivity and NPV are still 85% and 94% respectively.

CONCLUSION

In this retrospective well-defined cohort consisting of 91 patients we showed that the sentinel lymph node biopsy is an accurate diagnostic technique in detecting occult metastases in cT1-2N0 OSCC and is a save and reliable alternative to an END or watchful waiting.

REFERENCES

1. Schilling C, Stoeckli SJ, Haerle SK, Broglie MA, Huber GF, Sorensen JA, et al. Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer. *Eur J Cancer* 2015 Dec;51(18):2777-2784.
2. Broglie MA, Haile SR, Stoeckli SJ. Long-term experience in sentinel node biopsy for early oral and oropharyngeal squamous cell carcinoma. *Ann Surg Oncol* 2011 Oct;18(10):2732-2738.
3. Ganly I, Patel S, Shah J. Early stage squamous cell cancer of the oral tongue-clinicopathologic features affecting outcome. *Cancer* 2012 Jan 1;118(1):101-111.
4. Larsen SR, Johansen J, Sorensen JA, Krogdahl A. The prognostic significance of histological features in oral squamous cell carcinoma. *J Oral Pathol Med* 2009 Sep;38(8):657-662.
5. de Bree R, Nieweg OE. The history of sentinel node biopsy in head and neck cancer: From visualization of lymphatic vessels to sentinel nodes. *Oral Oncol* 2015 Sep;51(9):819-823.
6. Pedersen NJ, Jensen DH, Hedback N, Frendo M, Kiss K, Lelkaitis G, et al. Staging of early lymph node metastases with the sentinel lymph node technique and predictive factors in T1/T2 oral cavity cancer: A retrospective single-center study. *Head Neck* 2016 Apr;38 Suppl 1:E1033-40.
7. Flach GB, Bloemena E, Klop WM, van Es RJ, Schepman KP, Hoekstra OS, et al. Sentinel lymph node biopsy in clinically N0 T1-T2 staged oral cancer: the Dutch multicenter trial. *Oral Oncol* 2014 Oct;50(10):1020-1024.
8. Den Toom IJ, Heuveling DA, Flach GB, van Weert S, Karagozoglu KH, van Schie A, et al. Sentinel node biopsy for early-stage oral cavity cancer: the VU University Medical Center experience. *Head Neck* 2015 Apr;37(4):573-578.
9. van den Brekel MW, Castelijns JA, Stel HV, Golding RP, Meyer CJ, Snow GB. Modern imaging techniques and ultrasound-guided aspiration cytology for the assessment of neck node metastases: a prospective comparative study. *Eur Arch Otorhinolaryngol* 1993;250(1):11-17.
10. Schoder H, Carlson DL, Kraus DH, Stambuk HE, Gonen M, Erdi YE, et al. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. *J Nucl Med* 2006 May;47(5):755-762.
11. Woolgar JA, Beirne JC, Vaughan ED, Lewis-Jones HG, Scott J, Brown JS. Correlation of histopathologic findings with clinical and radiologic assessments of cervical lymph-node metastases in oral cancer. *Int J Oral Maxillofac Surg* 1995 Feb;24(1 Pt 1):30-37.
12. D'Cruz AK, Vaish R, Kapre N, Dandekar M, Gupta S, Hawaldar R, et al. Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer. *N Engl J Med* 2015 Aug 6;373(6):521-529.
13. Teymoortash A, Hoch S, Eivazi B, Werner JA. Postoperative morbidity after different types of selective neck dissection. *Laryngoscope* 2010 May;120(5):924-929.
14. Chone CT, Aniteli MB, Magalhaes RS, Freitas LL, Altemani A, Ramos CD, et al. Impact of immunohistochemistry in sentinel lymph node biopsy in head and

- neck cancer. *Eur Arch Otorhinolaryngol* 2013 Jan;270(1):313-317.
15. Liu M, Wang SJ, Yang X, Peng H. Diagnostic Efficacy of Sentinel Lymph Node Biopsy in Early Oral Squamous Cell Carcinoma: A Meta-Analysis of 66 Studies. *PLoS One* 2017 Jan 20;12(1):e0170322.
 16. Dutch Central Committee on Research Involving Human Subjects. Available at: <http://www.ccmo.nl/en/non-wmo-research>. Accessed August 11, 2017.
 17. Dutch guideline head and neck cancer 2014. Available at: <https://www.nvmka.nl/sites/www.nvmka.nl/files/Richtlijn%20Hoofd-halstumoren%202015.pdf>. Accessed March 30, 2017.
 18. Hermanek P, Hutter RV, Sobin LH, Wittekind C. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. *Cancer* 1999 Dec 15;86(12):2668-2673.
 19. Heerema MG, Melchers LJ, Roodenburg JL, Schuurin E, de Bock GH, van der Vegt B. Reproducibility and prognostic value of pattern of invasion scoring in low-stage oral squamous cell carcinoma. *Histopathology* 2016 Feb;68(3):388-397.
 20. Melchers LJ, Schuurin E, van Dijk BA, de Bock GH, Witjes MJ, van der Laan BF, et al. Tumour infiltration depth \geq 4 mm is an indication for an elective neck dissection in pT1cN0 oral squamous cell carcinoma. *Oral Oncol* 2012 Apr;48(4):337-342.
 21. Pezier T, Nixon IJ, Gurney B, Schilling C, Hussain K, Lyons AJ, et al. Sentinel lymph node biopsy for T1/T2 oral cavity squamous cell carcinoma—a prospective case series. *Ann Surg Oncol* 2012 Oct;19(11):3528-3533.
 22. Weiss MH, Harrison LB, Isaacs RS. Use of decision analysis in planning a management strategy for the stage N0 neck. *Arch Otolaryngol Head Neck Surg* 1994 Jul;120(7):699-702.
 23. Alkureishi LW, Ross GL, Shoaib T, Soutar DS, Robertson AG, Thompson R, et al. Sentinel node biopsy in head and neck squamous cell cancer: 5-year follow-up of a European multicenter trial. *Ann Surg Oncol* 2010 Sep;17(9):2459-2464.
 24. Civantos FJ, Zitsch RP, Schuller DE, Agrawal A, Smith RB, Nason R, et al. Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial. *J Clin Oncol* 2010 Mar 10;28(8):1395-1400.
 25. Stoeckli SJ, Huebner T, Huber GF, Broglie MA. Technique for reliable sentinel node biopsy in squamous cell carcinomas of the floor of mouth. *Head Neck* 2016 Sep;38(9):1367-1372.
 26. van den Berg NS, Brouwer OR, Klop WM, Karakullukcu B, Zuur CL, Tan IB, et al. Concomitant radio- and fluorescence-guided sentinel lymph node biopsy in squamous cell carcinoma of the oral cavity using ICG-(99m)Tc-nanocolloid. *Eur J Nucl Med Mol Imaging* 2012 Jul;39(7):1128-1136.
 27. Den Toom IJ, Bloemena E, van Weert S, Karagozoglu KH, Hoekstra OS, de Bree R. Additional non-sentinel lymph node metastases in early oral cancer patients with positive sentinel lymph nodes. *Eur Arch Otorhinolaryngol* 2017 Feb;274(2):961-968.
 28. Stoeckli SJ, Pfaltz M, Ross GL, Steinert HC, MacDonald DG, Wittekind C, et al. The second international conference on sentinel node biopsy in mucosal head

- and neck cancer. *Ann Surg Oncol* 2005 Nov;12(11):919-924.
29. Jefferson GD, Sollaccio D, Gomez-Fernandez CR, Civantos F, Jr. Evaluation of immunohistochemical fine sectioning for sentinel lymph node biopsy in oral squamous cell carcinoma. *Otolaryngol Head Neck Surg* 2011 Feb;144(2):216-219.
 30. Bell RB, Markiewicz MR, Dierks EJ, Gregoire CE, Rader A. Thin serial step sectioning of sentinel lymph node biopsy specimen may not be necessary to accurately stage the neck in oral squamous cell carcinoma. *J Oral Maxillofac Surg* 2013 Jul;71(7):1268-1277.
 31. Te Grootenhuis NC, van der Zee AG, van Doorn HC, van der Velden J, Vergote I, Zanagnolo V, et al. Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I. *Gynecol Oncol* 2016 Jan;140(1):8-14.
 32. Slomovitz BM, Coleman RL, Oonk MH, van der Zee A, Levenback C. Update on sentinel lymph node biopsy for early-stage vulvar cancer. *Gynecol Oncol* 2015 Aug;138(2):472-477.
 33. Van der Zee AG, Oonk MH, De Hullu JA, Ansink AC, Vergote I, Verheijen RH, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. *J Clin Oncol* 2008 Feb 20;26(6):884-889.
 34. Turrentine FE, Wang H, Simpson VB, Jones RS. Surgical risk factors, morbidity, and mortality in elderly patients. *J Am Coll Surg* 2006 Dec;203(6):865-877.
 35. Melkane AE, Mamelle G, Wycisk G, Temam S, Janot F, Casiraghi O, et al. Sentinel node biopsy in early oral squamous cell carcinomas: a 10-year experience. *Laryngoscope* 2012 Aug;122(8):1782-1788.
 36. Clausen MJ, Melchers LJ, Mastik MF, Slagter-Menkema L, Groen HJ, Laan BF, et al. RAB25 expression is epigenetically downregulated in oral and oropharyngeal squamous cell carcinoma with lymph node metastasis. *Epigenetics* 2016 Sep;11(9):653-663.
 37. Clausen MJ, Melchers LJ, Mastik MF, Slagter-Menkema L, Groen HJ, van der Laan BF, et al. Identification and validation of WISP1 as an epigenetic regulator of metastasis in oral squamous cell carcinoma. *Genes Chromosomes Cancer* 2016 Jan;55(1):45-59.
 38. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG. EpCAM in carcinogenesis: the good, the bad or the ugly. *Carcinogenesis* 2010 Nov;31(11):1913-1921.

